We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
Kisspeptin is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Kisspeptin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2009–2023 with a typical study size of 32 participants.
Based on 14 studies · 8 RCTs · 1,059 total participants
Confidence
HighBy outcome
Kisspeptin has an evidence score of 3/10 — emerging evidence based on 14 indexed studies. A hypothalamic neuropeptide (from the KISS1 gene) that sits at the top of the reproductive hormone axis — it stimulates GnRH neurons to release LH and FSH. It has a genuinely rigorous human-research record, largely from the Dhillo group at Imperial College London: kisspeptin-54 has been tested as an IVF egg-maturation trigger, in hypothalamic amenorrhea, and for sexual/emotional brain processing. Honest framing: this is legitimate investigational science, NOT an approved drug or a dietary supplement, and the grey-market 'libido peptide' sold online is not the supervised clinical product. Representative study: PMID 26192876.
The commonly studied dose of Kisspeptin is No consumer dose — investigational, used only in supervised research/clinical protocols. Trials used weight-based dosing (e.g. kisspeptin-54 6.4-12.8 nmol/kg subcutaneous as a single IVF trigger; kisspeptin-54 1 nmol/kg/h IV infusion in brain-processing studies).. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Last reviewed June 2026 · evidence from 14 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Kisspeptin (KISS1-derived neuropeptide)
A hypothalamic neuropeptide (from the KISS1 gene) that sits at the top of the reproductive hormone axis — it stimulates GnRH neurons to release LH and FSH. It has a genuinely rigorous human-research record, largely from the Dhillo group at Imperial College London: kisspeptin-54 has been tested as an IVF egg-maturation trigger, in hypothalamic amenorrhea, and for sexual/emotional brain processing. Honest framing: this is legitimate investigational science, NOT an approved drug or a dietary supplement, and the grey-market 'libido peptide' sold online is not the supervised clinical product.
Kisspeptin has unusually rigorous human research (phase-2 IVF and fMRI RCTs), but it remains an investigational research peptide with no approved consumer use or self-administration data — an emerging score.
Kisspeptin is the protein product of the KISS1 gene, signalling through the KISS1R receptor (also called GPR54) on hypothalamic gonadotropin-releasing-hormone (GnRH) neurons.
It is the principal upstream gatekeeper of the hypothalamic-pituitary-gonadal axis: kisspeptin neurons integrate sex-steroid, metabolic and circadian signals and drive the pulsatile and surge-mode release of GnRH that in turn controls luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
The two research forms are kisspeptin-54 (KP-54, the full-length cleaved peptide) and kisspeptin-10 (KP-10, the C-terminal decapeptide).
The human evidence is real and unusually rigorous for a 'research peptide': controlled studies — mostly from Waljit Dhillo's group at Imperial College London — have shown that a single subcutaneous dose of kisspeptin-54 can trigger final oocyte maturation in IVF, including phase-2 randomized trials in women at high risk of ovarian hyperstimulation syndrome (OHSS), where it produced mature eggs and live births with strikingly low OHSS rates.
Kisspeptin acutely stimulates gonadotropin release in women with hypothalamic amenorrhea (though chronic twice-daily dosing causes tachyphylaxis/desensitization), discriminates hypothalamic from pituitary dysfunction in men with congenital hypogonadotropic hypogonadism, and raises LH and testosterone in hypogonadal men with type 2 diabetes.
Separately, functional-MRI studies show kisspeptin modulates limbic 'sexual and emotional' brain processing and, in a randomized trial, improved sexual brain responses and penile tumescence in men with hypoactive sexual desire disorder (HSDD).
Despite this strong mechanistic and early-clinical base, kisspeptin is NOT an approved medicine and is NOT a regulated dietary supplement — it remains investigational, used in registered trials and academic IVF protocols.
The honest caution: a grey-market 'kisspeptin' is sold online as a libido/testosterone peptide, but self-administration is unstudied, sourcing is unregulated and potentially impure, there is no long-term safety data outside supervised trials, and the marketing hype runs well ahead of what the supervised human evidence actually supports.
Kisspeptin binds KISS1R (GPR54) on hypothalamic GnRH neurons, the upstream gatekeeper of the reproductive axis. This stimulates GnRH release, driving downstream pituitary gonadotropin (LH/FSH) secretion.
By stimulating an endogenous GnRH pulse/surge, kisspeptin elicits a physiological LH (and FSH) rise — the basis for its use as an IVF egg-maturation trigger and as a probe of hypothalamic function.
Beyond hormone release, kisspeptin modulates limbic brain structures (amygdala, hippocampus, globus pallidus, cingulate) involved in sexual and emotional behaviour, as shown by functional-MRI studies in humans.
How Kisspeptin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No consumer dose — investigational, used only in supervised research/clinical protocols. Trials used weight-based dosing (e.g. kisspeptin-54 6.4-12.8 nmol/kg subcutaneous as a single IVF trigger; kisspeptin-54 1 nmol/kg/h IV infusion in brain-processing studies).
Can be taken without food
| Form | Type |
|---|---|
| 💊Kisspeptin-54 (KP-54) | Recommended |
| 💊Kisspeptin-10 (KP-10) | Alternative |
KP-54 is the most extensively studied clinical form (IVF trigger, amenorrhea, hypogonadism, brain processing). KP-10 is shorter-acting and shows sex-dependent responses. Both are research peptides, not approved drugs or supplements.
Minimum: 1 days
Optimal: 1 days
Cycling: Not required
Note: Timing in research is dictated by the protocol (IVF trigger timed to oocyte retrieval; infusion timed to imaging). No at-home timing guidance exists because at-home use is not a studied or sanctioned scenario.
Dose-response data unavailable. The current published research for Kisspeptin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
A single dose reliably raises LH (and, in men, testosterone) within hours — robustly demonstrated in controlled human studies.
Kisspeptin-54 triggered mature-egg retrieval and live births in phase-2 IVF trials, with very low ovarian-hyperstimulation-syndrome rates — but this is a clinic-administered protocol, not self-use.
Randomized fMRI studies show enhanced limbic sexual-processing in men and women with HSDD — including increased penile tumescence and sexual-desire measures in men — early-stage, not an approved treatment.
Repeated twice-daily dosing caused tachyphylaxis (loss of LH response) in women with hypothalamic amenorrhea — a real limitation for any continuous-use 'libido' claim.
Avoid. The supervised clinical evidence does not validate self-administered grey-market kisspeptin; sourcing, purity and long-term safety are all unknown.
Only within a registered trial or specialist fertility protocol — never self-sourced.
Outside sanctioned reproductive-medicine use, avoid; safety in pregnancy for any non-protocol use is not established.
Kisspeptin acts on the same hypothalamic-pituitary-gonadal axis as GnRH analogues, hCG and gonadotropins; combining them (as in IVF) requires specialist supervision and dosing — not something to layer on at home.
Sex steroids feed back on kisspeptin/GnRH signalling; concurrent use could blunt or alter the gonadotropin response unpredictably.
Tip: Trial doses were generally well-tolerated; this does not extend to unsupervised self-dosing of grey-market product
Tip: Observed with chronic twice-daily dosing; avoid continuous regimens
Tip: Inherent to subcutaneous administration
Tip: Avoid non-pharmaceutical-grade sources entirely — purity, dose and sterility are unverified
Timing is flexible for Kisspeptin — consistent daily use matters more than the time of day. Dosing is entirely protocol-specific in research settings (e.g.
Kisspeptin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are well-tolerated in supervised trials (no serious adverse events reported), tachyphylaxis (loss of LH response) with repeated dosing, injection-site reactions. Use caution if any of these apply to you: Not for self-administration — investigational research peptide; Pregnancy/breastfeeding (outside its supervised reproductive use); Known hypersensitivity to the peptide or formulation excipients.
Gonadorelin
Mostly mechanism / observationalA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.